GSK announced that its experimental lung cancer drug, risvutatug rezetecan, achieved a 61% confirmed response rate at the higher 8 mg/kg dose in an early global trial involving patients with relapsed extensive-stage small cell lung cancer. This response rate is significantly higher compared to the 32% response at the lower 6 mg/kg dose. The drug targets the B7-H3 protein on tumor cells and is being evaluated in a global phase III trial. While the higher dose showed more serious treatment-related side effects, the safety profile remains manageable. GSK is advancing development of this drug across multiple cancer types, having treated over 1,000 patients so far.
As of Oct 19, 2026 13:41 WIB, GSK shares on Pluang trade at USD 49.51, up 3.43% for the day, closer to its 52-week low of $43.24 than the high of $61.18. This price level reflects a market still valuing GSK well below its peak despite the promising 61% response rate reported for its lung cancer drug in early trials. The stock's dividend yield stands at 3.67%, offering income alongside potential growth from its advancing drug pipeline.
